Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 June;64(3) > Minerva Cardioangiologica 2016 June;64(3):339-53

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Frequency: Bi-Monthly

ISSN 0026-4725

Online ISSN 1827-1618

 

Minerva Cardioangiologica 2016 June;64(3):339-53

    REVIEWS

Advances with polymer-free amphilimus-eluting stents

Didier CARRIÉ

Department of Cardiology, University Hospital Rangueil, Toulouse, France

Despite the improved clinical outcomes following the availability of second generation drug eluting stents (DES), percutaneous coronary intervention (PCI) is associated with worse clinical and angiographic outcomes among the patients with diabetes mellitus (DM) than among non-diabetics. The Cre8 Amphilimus-eluting DES is polymer-free, resulting in a reduced inflammatory response and lower risk of stent thrombosis. In a clinical study, it showed equivalent efficacy and safety in diabetic and non-diabetic populations, a unique finding among DES studies. These findings were confirmed in a real-world study, Investig8, and another real-world study, Particip8, is ongoing. The RESERVOIR Clinical Trial recruited patients with DM and showed noninferiority of the Cre8 DES compared to an everolimus eluting DES (EES) in the overall group but showed a statistical superiority of Cre8 in diabetic patients with higher metabolic dysfunctions. The Cre8 DES is therefore a valuable option for this important patient population.

language: English


FULL TEXT  REPRINTS

top of page